Certain Stock Options of Aytu BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2021.
January 10, 2021
Share
Certain Stock Options of Aytu BioPharma, Inc. are subject to a Lock-Up Agreement Ending on 10-JAN-2021. These Stock Options will be under lockup for 31 days starting from 10-DEC-2020 to 10-JAN-2021.
Details:
The executive officers and directors have agreed that they will not offer, sell, contract to sell, pledge or otherwise dispose of, directly or indirectly, any shares of common stock or securities convertible into or exchangeable or exercisable for any shares of common stock, for a period of 30 days after the date of the prospectus supplement without the prior written consent of H.C. Wainwright & Co, LLC.
Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Companyâs Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Companyâs prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.
AYTU BIOPHARMA, INC. 
